Flowers Cynthia Louise
Known title: DirectorCIK: 0001741455
Associated companies
Transaction History
| LSTA | ▲ Buy | Grant | 30,456 | $0 | 1/9/2026 | View on chart |
| LSTA | ▲ Buy | Grant | 15,789 | $0 | 1/9/2025 | View on chart |
| LSTA | ▲ Buy | Grant | 19,480 | $0 | 1/9/2024 | View on chart |
| LSTA | ▲ Buy | Grant | 20,000 | $0 | 1/9/2023 | View on chart |
| LSTA | ▲ Buy | Grant | 65,430 | $0 | 1/10/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
Lisata reports first patient dose in MAR002 acromegaly trial
Lisata Therapeutics announced that its subsidiary Marea Therapeutics has given the first dose of MAR002 to a patient in a Phase 2 trial for acromegaly. This marks the first clinical exposure of the drug and represents a key step toward potential regulatory approval. The announcement highlights progress in Lisata’s development pipeline, though the company remains in early stages of product development.
Lisata reports first patient dose in MAR002 acromegaly trial. Lisata Therapeutics announced that its subsidiary Marea Therapeutics has given the first dose of MAR002 to a patient in a Phase 2 trial for acromegaly. This marks the first clinical exposure of the drug and represents a key step toward potential regulatory approval. The announcement highlights progress in Lisata’s development pipeline, though the company remains in early stages of product development.